Our results confirm the therapeutic potential of inducing TLR3, since its triggering by IFN-1, and its subsequent activation by dsRNA effectively lead to OS and RMS tumor cell death in vitro and in vivo. This evidence concerns the gene TLR3 and neoplasm.